U.S. markets closed

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.00+0.36 (+2.85%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close12.64
Open12.60
Bid13.01 x 900
Ask13.02 x 1400
Day's Range12.45 - 13.01
52 Week Range9.72 - 20.50
Volume4,993,029
Avg. Volume3,540,544
Market Cap1.672B
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-1.04
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
    Business Wire

    Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

    VICTORIA, British Columbia, Jun 14, 2021--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. ("BioMarin"), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-t

  • Aurinia Announces Results of the 2021 Annual General Meeting
    Business Wire

    Aurinia Announces Results of the 2021 Annual General Meeting

    Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the "Meeting") held on June 7, 2021.

  • Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
    Business Wire

    Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress

    Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) 2021 Congress. The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology (EULAR) 2021 Congress.